iridal: a plant triterpenoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5318463 |
| CHEMBL ID | 1173373 |
| MeSH ID | M0449009 |
| Synonym |
|---|
| iridal |
| (2z)-2-[(2r,3s,4s)-4-hydroxy-2-(3-hydroxypropyl)-3,4-dimethyl-3-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]cyclohexylidene]propanal |
| CHEMBL1173373 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID492440 | Antimalarial activity against Plasmodium falciparum after 48 hrs | 2009 | Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9 | Antimalarials from nature. |
| AID492423 | Antimalarial activity against Plasmodium falciparum after 32 hrs | 2009 | Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9 | Antimalarials from nature. |
| AID492424 | Antimalarial activity against Plasmodium falciparum after 72 hrs | 2009 | Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9 | Antimalarials from nature. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (25.93) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.57%) | 6.00% |
| Case Studies | 2 (7.14%) | 4.05% |
| Observational | 1 (3.57%) | 0.25% |
| Other | 24 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. | 3.53 | 2 | 0 | aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug |
| ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11. | 3.14 | 1 | 0 | indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene | antineoplastic agent; plant metabolite |
| histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3. | 7.07 | 1 | 0 | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine. | 7.07 | 1 | 0 | aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite |
| acrolein [no description available] | 2.06 | 1 | 0 | enal | herbicide; human xenobiotic metabolite; toxin |
| cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton. | 2.06 | 1 | 0 | cyclohexanols; secondary alcohol | solvent |
| cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution. | 2.58 | 2 | 0 | cycloalkane; cyclopentanes; volatile organic compound | non-polar solvent |
| galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils. | 3.14 | 1 | 0 | benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound | antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite |
| plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively. | 3.14 | 1 | 0 | hydroxy-1,4-naphthoquinone; phenols | anticoagulant; antineoplastic agent; immunological adjuvant; metabolite |
| cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. | 3.14 | 1 | 0 | bisbenzylisoquinoline alkaloid; isoquinolines | |
| alpha-terpineol terpineol : A family of monoterpenols that have a p-menthane skeleton containing one double bond and bearing a single hydroxy substituent. | 2.11 | 1 | 0 | terpineol | plant metabolite |
| helenalin helenalin: toxic principle of Helenium microcephalum (smallhead sneezeweed); structure. helenalin : A sesquiterpene lactone that is 3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione substituted by a hydroxy group at position 4, methyl groups at positions 4a and 8 and a methylidene group at position 3 (the 3aS,4S,4aR,7aR,8R,9aR stereoisomer).. NF-kappaB inhibitor : An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA. | 3.14 | 1 | 0 | cyclic ketone; gamma-lactone; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone | anti-inflammatory agent; antineoplastic agent; metabolite; plant metabolite |
| palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46. | 2.04 | 1 | 0 | metal allergen; nickel group element atom; platinum group metal atom | |
| tetrahydropalmatine [no description available] | 3.14 | 1 | 0 | an (S)-7,8,13,14-tetrahydroprotoberberine; berberine alkaloid; organic heterotetracyclic compound | adrenergic agent; dopaminergic antagonist; non-narcotic analgesic |
| lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity. | 3.14 | 1 | 0 | indolizidine alkaloid | anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor |
| pinostrobin [no description available] | 3.14 | 1 | 0 | monohydroxyflavanone; monomethoxyflavanone | antidote; plant metabolite |
| cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group. | 3.14 | 1 | 0 | indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound | anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite |
| 3,4-(dichloro)-5-hydroxy-2(5h)-furanone 3,4-(dichloro)-5-hydroxy-2(5H)-furanone: structure given in first source | 3.14 | 1 | 0 | ||
| phomenone phomenone: structure | 3.14 | 1 | 0 | sesquiterpenoid | |
| diisocyanoadociane diisocyanoadociane: RN given for (1R-(1alpha,2alpha,3abeta,5alpha,5aalpha,8alpha,8aalpha,10abeta,10balpha,10cbeta))-isomer; structure in first source | 3.14 | 1 | 0 | ||
| norcoralydine norcoralydine: neuromuscular blocking agent; RN given refers to (S)-isomer; structure | 3.14 | 1 | 0 | alkaloid | |
| anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. | 3.14 | 1 | 0 | monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic | anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor |
| lupeol [no description available] | 3.14 | 1 | 0 | pentacyclic triterpenoid; secondary alcohol | anti-inflammatory drug; plant metabolite |
| dentatin dentatin: from Clausena excavata; structure in first source | 3.14 | 1 | 0 | coumarins | metabolite |
| hemanthamine [no description available] | 3.14 | 1 | 0 | alkaloid | |
| y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme. | 2.06 | 1 | 0 | aromatic amide | |
| racemosol racemosol: from Bauhinia malabarica Roxb; don't confuse with stemanthrene D from STEMONA that was sometimes called racemosol; | 3.14 | 1 | 0 | ||
| catechin gallate catechin gallate: structure in first source. (+)-catechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3S)-hydroxy group of (+)-catechin. | 3.14 | 1 | 0 | flavans; gallate ester; polyphenol | metabolite |
| acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin. | 3.14 | 1 | 0 | dihydroxyflavone; monomethoxyflavone | anticonvulsant; plant metabolite |
| 7,3'-dihydroxy-4'-methoxyisoflavone 7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position. | 3.14 | 1 | 0 | 4'-methoxyisoflavones; 7-hydroxyisoflavones | antioxidant; metabolite |
| luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. | 3.14 | 1 | 0 | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
| genistein [no description available] | 3.14 | 1 | 0 | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor |
| budlein a budlein A: anti-inflammatory and analgesic sesquiterpene lactone from Viguiera robusta; structure in first source | 3.14 | 1 | 0 | sesquiterpenoid | |
| mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. | 3.14 | 1 | 0 | aromatic ether; phenols; xanthones | antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite |
| cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function. | 3.14 | 1 | 0 | epoxide; monocarboxylic acid amide | antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor |
| clausarin clausarin: isolated from Enkleia siamensis; structure given in first source | 3.14 | 1 | 0 | ||
| tazettine tazettine: from Amaryllidaceae | 3.14 | 1 | 0 | indole alkaloid fundamental parent; indole alkaloid | |
| cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3. | 7.07 | 1 | 0 | cysteinium | fundamental metabolite |
| 4-hydroxylonchocarpin 4-hydroxylonchocarpin: structure in first source | 3.14 | 1 | 0 | ||
| dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization. | 3.14 | 1 | 0 | 1,3-thiazoles; tetrapeptide | animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent |
| mer nf5003f stachybotrydial: a pancreatic cholesterol esterase inhibitor; also inhibits fucosyltransferase and sialyltransferase; structure in first source | 3.14 | 1 | 0 | ||
| lepadin f lepadin F: cis-decahydroquinoline alkaloid from the Australian ascidian Aplidium tabascum; structure in first source | 3.14 | 1 | 0 | ||
| 2',3,4,4'-tetrahydroxy-5-prenylchalcone [no description available] | 3.14 | 1 | 0 | ||
| veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal. | 2.15 | 1 | 0 | ||
| 3-epioleanolic acid [no description available] | 3.14 | 1 | 0 | triterpenoid | metabolite |
| dehydroabietinol dehydroabietinol: Isolated from Hyptis suaveolens; structure in first source | 3.14 | 1 | 0 | abietane diterpenoid; carbotricyclic compound | |
| neo-kauluamine neo-kauluamine: manzamine alkaloid with potent activity against infectious diseases; structure in first source | 3.14 | 1 | 0 | ||
| eurycomanone [no description available] | 3.14 | 1 | 0 | cyclic ether; delta-lactone; enone; organic heteropentacyclic compound; pentol; quassinoid; secondary alcohol; secondary alpha-hydroxy ketone; tertiary alcohol | antimalarial; antineoplastic agent; metabolite |
| pycnidione pycnidione: potentiator of bleomycin; isolated from Gloeotinia; structure in first source | 3.14 | 1 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Iris Neoplasms Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi. | 0 | 2.31 | 1 | 0 |
| Day Blindness [description not available] | 0 | 2.17 | 1 | 0 |
| Abnormalities, Congenital [description not available] | 0 | 2.34 | 2 | 0 |
| Eye Abnormalities Congenital absence of or defects in structures of the eye; may also be hereditary. | 0 | 2.33 | 2 | 0 |
| Iris Diseases Diseases, dysfunctions, or disorders of or located in the iris. | 0 | 3.72 | 11 | 0 |
| Deaf Mutism [description not available] | 0 | 3.03 | 5 | 0 |
| Epiphora [description not available] | 0 | 2.84 | 4 | 0 |
| Albinism, Cutaneous [description not available] | 0 | 2.84 | 4 | 0 |
| Albinism, Tyrosinase-Negative [description not available] | 0 | 2.84 | 4 | 0 |
| Albinism General term for a number of inherited defects of amino acid metabolism in which there is a deficiency or absence of pigment in the eyes, skin, or hair. | 0 | 2.84 | 4 | 0 |
| Deafness A general term for the complete loss of the ability to hear from both ears. | 0 | 3.03 | 5 | 0 |
| Lacrimal Apparatus Diseases Diseases of the LACRIMAL APPARATUS. | 0 | 2.84 | 4 | 0 |
| Albinism, Oculocutaneous Heterogeneous group of autosomal recessive disorders comprising at least four recognized types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. The two most common are the tyrosinase-positive and tyrosinase-negative types. | 0 | 2.84 | 4 | 0 |
| Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. | 0 | 2.84 | 4 | 0 |
| Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed) | 0 | 2.84 | 4 | 0 |
| Alopecia Cicatrisata [description not available] | 0 | 1.93 | 1 | 0 |
| Alopecia Circumscripta [description not available] | 0 | 1.93 | 1 | 0 |
| Cataract, Membranous [description not available] | 0 | 1.93 | 1 | 0 |
| Eyelid Diseases Diseases involving the EYELIDS. | 0 | 1.93 | 1 | 0 |
| Alopecia Absence of hair from areas where it is normally present. | 0 | 6.93 | 1 | 0 |
| Alopecia Areata Loss of scalp and body hair involving microscopically inflammatory patchy areas. | 0 | 1.93 | 1 | 0 |
| Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed) | 0 | 6.93 | 1 | 0 |
| Arachnodactyly An abnormal bone development that is characterized by extra long and slender hands and fingers, such that the clenched thumb extends beyond the ulnar side of the hand. Arachnodactyly can include feet and toes. Arachnodactyly has been associated with several gene mutations and syndromes. | 0 | 1.94 | 1 | 0 |
| Coloboma Congenital anomaly in which some of the structures of the eye are absent due to incomplete fusion of the fetal intraocular fissure during gestation. | 0 | 6.94 | 1 | 0 |
| Eye Disorders [description not available] | 0 | 1.94 | 1 | 0 |
| Marfan Syndrome, Type I [description not available] | 0 | 1.94 | 1 | 0 |
| Cleft Spine [description not available] | 0 | 1.94 | 1 | 0 |
| Incontinentia Pigmenti Achromians [description not available] | 0 | 1.94 | 1 | 0 |
| Eye Diseases Diseases affecting the eye. | 0 | 1.94 | 1 | 0 |
| Marfan Syndrome An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2. | 0 | 1.94 | 1 | 0 |
| Cystadenoma, Papillary A benign neoplasm of the ovary. | 0 | 1.94 | 1 | 0 |
| Cancer of Eye [description not available] | 0 | 1.94 | 1 | 0 |
| Lymph Node Metastasis [description not available] | 0 | 1.94 | 1 | 0 |
| Benign Neoplasms [description not available] | 0 | 1.94 | 1 | 0 |
| Papilloma, Squamous Cell [description not available] | 0 | 1.94 | 1 | 0 |
| Eyelid Neoplasms Tumors of cancer of the EYELIDS. | 0 | 1.94 | 1 | 0 |
| Local Neoplasm Recurrence [description not available] | 0 | 1.94 | 1 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 1.94 | 1 | 0 |
| Papilloma A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed) | 0 | 1.94 | 1 | 0 |
| Aura [description not available] | 0 | 1.93 | 1 | 0 |
| Symptom Cluster [description not available] | 0 | 1.93 | 1 | 0 |
| Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) | 0 | 6.93 | 1 | 0 |
| Syndrome A characteristic symptom complex. | 0 | 6.93 | 1 | 0 |